Punjab-Based Company Booked For Producing ‘Substandard’ Antibiotic

Noida: The drugs control department of Gautam Budh Nagar on Tuesday booked a Mohali-based pharmaceutical company for allegedly producing “substandard” quality antibiotics, which were found being sold in Gautam Budh Nagar.

The medicine ‘AZitas (azithromycin)’ which is commonly used to treat infections, was being sold at the medical stores operating in Gautam Budh Nagar, and was found to be of ‘substandard’ quality during assessment, informed officials.

Inspections are ongoing under the directions of the food safety and drug administration department and Gautam Budh Nagar district magistrate Manish Kumar Verma, to ensure drugs being sold at medical stores and pharmacies in the district were meeting the safety standards.

A case has been registered against the errant manufacturer under Drugs and Cosmetics Act, 1940, and further legal action is underway, said Vaibhav Babbar, drug inspector, Gautam Budh Nagar.

“The assessment of the AZitas tablet revealed that the drug was of substandard quality and unfit for consumption. Manufacturing and selling of drugs which are unsuitable for consumption is prohibited and is a violation under Section 18 (prohibition of manufacture and sale of certain drugs and cosmetics),” Babbar, adding that the offence is punishable under Section 27 of the Drugs and Cosmetics Act, 1940.

The drugs control department of Gautam Budh Nagar last week registered a case against two manufacturers/producers based in Himachal Pradesh for allegedly manufacturing and selling ‘unfit’ antibiotic medicines.

Inspections at medical stores and pharmacies revealed the two medicines, “moxfaith” and ”moxaveri”, were ‘substandard’ or ‘adulterated’ and unsafe for consumption.

The drugs were confiscated and the two manufacturing companies were booked under relevant sections of the Drugs and Cosmetics Act, 1940.

Related Posts

  • Pharma
  • July 16, 2025
  • 133 views
Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Generic drugmakers Aurobindo Pharma, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries. This follows ViiV Healthcare, a company focused…

  • Pharma
  • July 16, 2025
  • 42 views
Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

The pharma sector will be in focus on July 16, after Donald Trump said that pharmaceuticals tariffs would be implemented soon. Shares of pharmaceutical companies traded flat on Wednesday, July…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S.

Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S.

Aurobindo Pharma to manufacture, supply long acting HIV treatment drug

Aurobindo Pharma to manufacture, supply long acting HIV treatment drug

Famous Vaidyaratnam Ayurveda Clinic in Delhi is now more Accessible to Patients

Famous Vaidyaratnam  Ayurveda  Clinic in Delhi is now more Accessible to Patients